Molecular Basis of Differential Sensitivity of Myeloma Cells to Clinically Relevant Bolus Treatment with Bortezomib

Lignende værker

• Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib
  af: Mirabella, Anne C., et al.
  Udgivet: (2011)
• Selective inhibitor of proteasome’s caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites
  af: Britton, Matthew, et al.
  Udgivet: (2009)
• An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors
  af: Downey-Kopyscinski, Sondra, et al.
  Udgivet: (2018)
• The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells
  af: Kraus, Marianne, et al.
  Udgivet: (2015)
• Bortezomib in the management of multiple myeloma
  af: Jacob P Laubach, et al.
  Udgivet: (2009-09-01)